NCT01529671View on ClinicalTrials.gov

A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Pain
Interventions
DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily (BID)

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension BID

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01529671 - A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee | Biotech Hunter | Biotech Hunter